openPR Logo
Press release

Cardiovascular Stents Market — Trends, 2017–2025

09-22-2017 02:06 PM CET | Health & Medicine

Press release from: Medical Device By CMI

When a coronary artery is narrowed by the accumulation of fatty acids, also known as plaque, the blood flow to heart is reduced which result in the chest pain and if the blockage increases the blood flow to the heart is further reduced and might lead to cardiac arrest. To reduce the chances of heart attack, a tiny wire mesh tube is inserted in the artery with a balloon catheter, called cardiovascular stents. The balloon inflates, stent expands and keeps the artery open, which helps in the proper flow of blood to the heart. The patients undergoing angioplasty and stents has a quick rate of recovery as the stents prevents the re-narrowing of the arteries compared with the patients who has cardiovascular artery bypass surgery.
Increasing cardiovascular surgeries leads to higher market value for cardiovascular stents
Many people are diagnosed by cardiovascular disease nowadays, it is important to develop new medical instruments and solutions which will help cure those diseases. Therefore the use of coronary or cardiovascular stents is adopted in clinical practices which should have the clinical evidence, improved outcomes and physician’s experience. One of the drawback for the cardiovascular stent market is the increase prices of coronary stents. However, by using cost –containment policies and appropriateness criteria they can reduce the cost and in future the price of cardiovascular stents will decrease. The increasing geriatric population in the countries will be one of the reason to enhance the growth of this market. China has more number of aged people so stents producers are more likely to tap this market. According to WHO report in 2015 people died from cardiovascular diseases, representing 31% of all global deaths. On the preventions measures for this the global cardiovascular stents market is expected to grow in the future.

Request a sample copy of this report@
https://www.coherentmarketinsights.com/insight/request-sample/470

Drug Eluting Stents have much better angiographic and clinical results as compared to other type of segment in the cardiovascular stents Market
The global cardiovascular stents market is segmented on the basis of product type:
Drug Eluting stents,Bare Metal Stents,Bio-absorbable stents
The global cardiovascular stents market is segmented on the basis of material type
Carbon,Silicon carbide,Titanium Nitride Oxide,Cobalt Chromium,Platinum Chromium,Other stents
The global cardiovascular stent market is segmented on the basis of end user
Hospitals,Cardiac centers,Ambulatory surgical centers
Drug eluting absorbable metal scaffold, a new class of absorbable metal scaffold
According to the technological trends of  cardiovascular stents  market,  Bio -absorbable Polymer-coated drug Eluting Stents become available in the US market, which are the enfold  type of DES. The Circulatory System Devices Panel of the FDA’s Medical Devices Advisory Committee has approved application for the Absorb GT1 Bioresorbable Vascular Scaffold System. The DREAMS (Drug-Eluting Absorbable Metal Scaffold) device is a fully bioresorbable scaffold made from a magnesium alloy covered with a polymer and sirolimus drug  coating, this new class of absorbable metal scaffolds has the potential to become available in the United State market.  The stent-on –wire is also a new type of coronary stent available which is a Drug eluting coronary fixed wire systems. There are some other coronary stents newly developed which are Tryton Side Branch Stent, PK Papyrus Covered Stent.
Major players to lead in the cardiovascular stents market
The key players operating the cardiovascular stents market include Medtronic, St. Jude Medical, Boston scientific, and Edward Lifesciences, Abbott laboratories, Johnson &Johnson, Getinge, Terumo, W. L. Gore & Associates, and Lepu Medical Technology.

Get Discount On This Report:
https://www.coherentmarketinsights.com/insight/request-discount/470

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cardiovascular Stents Market — Trends, 2017–2025 here

News-ID: 734856 • Views: 182

More Releases from Medical Device By CMI

Custom Procedure Trays and Packs Market – Insights
Increasing number of surgical procedures is fuelling the adoption of custom procedure trays and packs (CPTP) market during the forecast period. For instance, according to the WHO, global volume of the surgeries performed in 2012 was estimated to 266.2 to 359.5 million, out of which one in every 20 operations globally was done in very-low-expenditure Member States. Increase in geriatric population, who are more likely to develop chronic wounds as they
Robotic Rehabilitation and Assistive Technologies Market, By Product Type
Rehabilitation robotics and assistive technologies allow for use of robotic devices for rehabilitation of patients suffering from mobility issues. Robotic rehabilitation and assistive technologies allow for application of robotics in therapeutic procedures to help with recovery a person from various diseases or disabilities such orthopedic traumas, neuromotor disorders, cognitive diseases, strokes and spinal cord injury. Assistive robotics allows people suffering from degenerative motor and/or cognitive abilities to lead an independent
Spectrophotometer Market : Moving Towards a Brighter Future
North America is expected to hold dominant position in the market and is also expected to show significant growth in the spectrometer market, due to increasing launch of novel products in the region by key players. For instance, in February 2018, Thermo Fisher Scientific, a U.S.-based company, launched TSQ 9000 Triple Quadrupole GC-MS/MS System. This system has been designed to increase productivity, with enhanced sensitivity, and it also reduces maintenance
Clinical Mass Spectrometry: Innovative Solution for Diverse Medical Applications
Clinical Mass Spectrometry: Innovative Solution for Diverse Medical Applications Clinical mass spectrometry serves as a quantitative and qualitative analytical tool for assessment of complex mixtures in all the phases of drug development, including identification of the lead compound and their conformational details. Clinical laboratories use automation for the management of large number of samples through, either total automation systems or high level analyzer automation that are offered by clinical mass spectrometers

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning